UWCCC Developmental Therapeutics (DT) Program Summary Co-Leaders: Glenn Liu, Shigeki Miyamoto, and Jing Zhang PROJECT SUMMARY/ABSTRACT The mission of the UW Carbone Cancer Center (UWCCC) Developmental Therapeutics (DT) Program is to improve cancer patient outcomes by discovering new targets, developing therapeutic agents and biomarkers, and translating this research into early phase clinical trials. The DT Program provides the translational direction not only for DT members, but for other programs within the UWCCC (e.g. GEM, VR, TM). Clinical trial data and resources inform our understanding of response and resistance mechanisms and enable the identification of new therapeutic targets and treatment strategies to improve clinical outcomes. The DT Program has 59 core members, representing 18 departments and 5 different schools/colleges. Research impacts of DT members are evidenced by research awards totaling over $22.5M in annual direct cost of peer-reviewed and non-peer reviewed funding (including $3.45M NCI, $6.2M cancer-related other NIH agencies, $4.97M peer-reviewed non-NIH sources, $7.9M non-peer reviewed funding) and a significant number of publications (1228 publications, 18% of which result from intra-programmatic collaboration and 24% from inter-programmatic work). A key component of the new UWCCC Strategic Operating Plan is to further strengthen and develop Innovative Therapies and Cancer Biomarkers. Consistent with this strategic goal, the thematic aims of the DT Program are to: 1) discover new molecular targets for cancer therapy; 2) develop new agents and biomarkers; and 3) translate new therapies and biomarkers into clinical trials. To achieve this goal, it is critical to have a very strong program that discovers, develops, and translates novel interventions and biomarkers. To this end, members of the DT Program come from basic science, applied science, and clinical departments. This program has expertise ranging from basic discovery (molecular pathways and targets), to development (drugs/assays/biomarkers), to early clinical translation application (Phase 1 clinical trials). Translational and clinical research DT program members apply intra- and inter-programmatic research discoveries in clinical trials, performing the majority of first-in-human or early phase clinical trials, while individual disease-specific research teams (Disease Oriented Teams) focus primarily on phase 2 and 3 studies. DT members lead or participate in all clinical research groups facilitating both translational and reverse-translational opportunities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014520-45
Application #
9706771
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-04-01
Budget End
2020-03-31
Support Year
45
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Wisconsin Madison
Department
Type
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Wu, Yirong; Fan, Jun; Peissig, Peggy et al. (2018) Quantifying predictive capability of electronic health records for the most harmful breast cancer. Proc SPIE Int Soc Opt Eng 10577:
Fu, Anqi; Oberholtzer, Sydney M; Bagheri-Fam, Stefan et al. (2018) Dynamic expression patterns of Irx3 and Irx5 during germline nest breakdown and primordial follicle formation promote follicle survival in mouse ovaries. PLoS Genet 14:e1007488
Ni, Dalong; Jiang, Dawei; Kutyreff, Christopher J et al. (2018) Molybdenum-based nanoclusters act as antioxidants and ameliorate acute kidney injury in mice. Nat Commun 9:5421
Huynh, Mailee; Pak, Chorom; Markovina, Stephanie et al. (2018) Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-?B activity and increases drug resistance in multiple myeloma. J Biol Chem 293:2452-2465
Farrell, Emily; Armstrong, Annie E; Grimes, Adrian C et al. (2018) Transcriptome Analysis of Cardiac Hypertrophic Growth in MYBPC3-Null Mice Suggests Early Responders in Hypertrophic Remodeling. Front Physiol 9:1442
Net, Jose M; Whitman, Gary J; Morris, Elizabteh et al. (2018) Relationships Between Human-Extracted MRI Tumor Phenotypes of Breast Cancer and Clinical Prognostic Indicators Including Receptor Status and Molecular Subtype. Curr Probl Diagn Radiol :
Jiang, Dawei; Ge, Zhilei; Im, Hyung-Jun et al. (2018) DNA origami nanostructures can exhibit preferential renal uptake and alleviate acute kidney injury. Nat Biomed Eng 2:865-877
Seok, Seung-Hyeon; Ma, Zhi-Xiong; Feltenberger, John B et al. (2018) Trace derivatives of kynurenine potently activate the aryl hydrocarbon receptor (AHR). J Biol Chem 293:1994-2005
Chapelin, Fanny; Capitini, Christian M; Ahrens, Eric T (2018) Fluorine-19 MRI for detection and quantification of immune cell therapy for cancer. J Immunother Cancer 6:105
Ni, Dalong; Ferreira, Carolina A; Barnhart, Todd E et al. (2018) Magnetic Targeting of Nanotheranostics Enhances Cerenkov Radiation-Induced Photodynamic Therapy. J Am Chem Soc 140:14971-14979

Showing the most recent 10 out of 1528 publications